No Data
No Data
UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now
UroGen Receives New U.S. Patent Allowance For Next-Generation Mitomycin-Based Products Expected To Provide Protection Until December 2041
UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
UroGen Pharma to Present at Upcoming Investor Conferences
Guggenheim Initiates UroGen Pharma Ltd(URGN.US) With Buy Rating, Announces Target Price $40
No Data
No Data